Two new antidepressants, mirtazapine and venlafaxine;Twee nieuwe antidepressiva: Mirtazapine en venlafaxine

Nederlands Tijdschrift voor Geneeskunde

Volumn 143, Issue 18, 1999, Pages 934-937

  Birkenhager T K ^a   Moleman, P ^a  

^a Stichting RBC   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; ANTIDEPRESSANT AGENT; MIRTAZAPINE; NORADRENALIN; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; OUTPATIENT; PATIENT COMPLIANCE; PRESYNAPTIC NERVE; PSYCHOSIS; REVIEW;

ADRENERGIC ALPHA-ANTAGONISTS; BENZAMIDES; CYCLOHEXANOLS; DEPRESSIVE DISORDER; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIANSERIN; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITORS; PSYCHOTIC DISORDERS; SEROTONIN SYNDROME; SEROTONIN UPTAKE INHIBITORS;

EID: 18844477263     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Song F, Freemantle N, Sheldon TA, House A, Watson P, Long A, et al. Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. BMJ 1993;306:683-7.
2. Benkert O, Grunder G, Wetzel H, Hackett D. A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia. J Psychiatr Res 1996;30:441-51.
3. Hirschfeld RA. Controversies in the diagnosis and treatment of severe depression. J Clin Psychiatry 1996;57:554-61.
4. Haddjeri N, Blier P, De Montigny C. Noradrenergic modulation of central serotonergic neurotransmission: acute and long-term actions of mirtazapine. Int Clin Psychopharmacol 1995;10 Suppl 4:11-7.
5. Claghorn JL, Lesern MD. A double-blind placebo-controlled study of Org 3770 in depressed outpatients. J Affect Disord 1995;34:165-71.
6. Marttila M, Jääskelainen J, Järvi R, Romanov M, Miettinen E, Sorri P, et al. A double-blind study comparing the efficacy and tolerability of mirtazapine and doxepin in patients with major depression. Eur Neuropsychopharmacol 1995;5:441-6.
7. Smith WT, Glaudin V, Panagides J, Gilvary E. Mirtazapine vs amitriptyline vs placebo in the treatment of major depressive disorder. Psychopharmacol Bull 1990;26:191-6.
8. Mullin J, Lodge A, Bennie E, McCreadie R, Bhatt GS, Fenton G. A multicentre double-blind, amitriptyline-controlled study of mirtazapine in patients with major depression. J Psychopharmacol 1996; 10:235-40.
9. Bremner JD. A double-blind comparison of Org 3770, amitriptyline, and placebo in major depression. J Clin Psychiatry 1995;56:519-25.
10. Moffaert M van, Wilde J de, Vereecken A, Dierick M, Evrard JL, Wilmotte J, et al. Mirtazapine is more effective than trazodone: a double-blind controlled study in hospitalized patients with major depression. Int Clin Psychopharmacol 1995;10:3-9.
11. Richou H, Ruimy P, Charbaut J, Delisle JP, Brunner H, Patris M, et al. A multicentre double-blind clomipramine-controlled efficacy and safety study of Org 3770. Hum Psychopharmacol 1995;10:263-71.
12. Zivkov M, Jongli GD de. Org 3770 versus amitriptyline: a 6-week randomized double-blind multicentre trial in hospitalized depressed patients. Hum Psychopharmacol 1995;10:173-80.
13. Bruijn JA, Moleman P, Mulder PG, Broek WW van den, Hulst AM van, Mast RC van der, et al. A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients. Psychopharmacology (Berl) 1996;127:231-7.
14. Montgomery SA. Safety of mirtazapine: a review. Int Clin Psychopharmacol 1995;10 Suppl 4:37-45.
15. Rudorfer M, Potter W. The role of metabolites of antidepressants in the treatment of depression. CNS Drugs 1997;7:273-312.
16. Mendlewicz J. Pharmacologic profile and efficacy of venlafaxine. Int Clin Psychopharmacol 1995;10 Suppl 2:5-13.
17. Schweizer E, Feighner J, Mandos LA, Rickels K. Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J Clin Psychiatry 1994;55:104-8.
18. Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, et al. A comparison of venlafaxine, trazodone, and placebo in major depression. J Clin Psychopharmacol 1994;14:99-106.
19. Schweizer E, Weise C, Clary C, Fox I, Rickels K. Placebo-controlled trial of venlafaxine for the treatment of major depression. J Clin Psychopharmacol 1991;11:233-6.
20. Khan A, Fabre LF, Rudolph R. Venlafaxine in depressed outpatients. Psychopharmacol Bull 1991;27:141-4.
21. Mendels J, Johnston R, Mattes J, Riesenherg R. Efficacy and safety of b.i.d. doses of vcnlafaxine in a dose-response study. Psychopharmacol Bull 1993;29:169-74.
22. Dierick M, Ravizza L, Realini R, Martin A. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog Neuropsychopharmacol Biol Psychiatry 1996;20:57-71.
23. Clerc GE, Ruimy P, Verdeau-Palles J. A double-blind comparison of venlafaxine and fluoxeline in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group. Int Clin Psychopharmacol 1994;9:139-43.
24. Guelfi JD, White C, Hacked D, Guichoux JY, Magni G. Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. J Clin Psychiatry 1995;56:450-8.
25. Hodgman MJ, Martin TG, Krenzelok EP. Serotonin syndrome due to venlafaxine and maintenance tranylcypromine therapy. Hum Exp Toxicol 1997;16:14-7.
26. Pollack MH. Worthinglon 3rd JJ, Otto MW, Maki KM, Smoller JW, Manfro GG, et al. Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study. Psychopharmacol Bull 1996;32:667-70.